QIAGEN welcomes new decision by U.S. Centers for Disease Control to use modern blood-based TB tests for immigration screening
Germantown, Maryland, and Hilden, Germany, February 20th, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed a decision by the U.S. Centers for Disease Control (CDC) to require the use of modern blood-based tests (IGRA) for tuberculosis (TB) screening. QIAGEN’s QuantiFERON-TB® Gold Plus (QFT-Plus®), the gold standard and market... Read more